Versions
- 2024-12-31 (2)
- 2024-12-31 (1)
Keywords
How to Cite
Abstract
Background: Hemodialysis (HD) is the primary treatment modality for patients with end-stage renal disease (ESRD) worldwide. Among HD patients, bloodborne infections—particularly hepatitis C virus (HCV)—are a major cause of morbidity and mortality. This study aimed to determine the prevalence of HCV among individuals undergoing HD and to identify the key associated risk factors.
Methodology: A total of 109 patients undergoing hemodialysis were included in this study, with an equal distribution of male and female participants. HCV infection status was assessed for each individual. Data analysis was conducted using SPSS version 21. Analysis of Variance (ANOVA) was used to interpret the results. Quantitative variables were summarized using means and standard deviations, while qualitative variables were presented as percentages.
Results: Among the 109 participants, 42 were female and 67 were male. HCV testing revealed that 18 males and 8 females were positive for active HCV infection, whereas 49 males and 34 females tested negative. The majority of the patients were from Bharakahu (n = 35), Abbottabad (n = 23), and Islamabad (n = 18). Other patients were from Fatehjang (n = 1), Khushab (n = 1), and Mardan (n = 2).
Conclusion: The study categorized populations based on their regional risk of acquiring HCV infection. The findings indicate that the overall prevalence of HCV infection among the study group was not significantly high. However, risk factors commonly associated with medical interventions were frequently observed, highlighting their relevance in the transmission of HCV among HD patients.
References
Singh P. Prevalence of HCV Infection among Patients of Medical College in NCR, Meerut, India. 2019;8(11):324-327
Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end‐stage renal disease. Journal of gastroenterology and hepatology. 2011;26(2):228-39.
Lohmann V. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Medical microbiology and immunology. 2019;208(1):3-24.
Sivakrishnan S, Pharm M. Liver disease overview. World Journal of Pharmacy and Pharmaceutical Sciences. 2019;8(1):1385-95.
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of hepatology. 2021;75(4):829-39.
Jin F, Dore GJ, Matthews G, Luhmann N, Macdonald V, Bajis S, Baggaley R, Mathers B, Verster A, Grulich AE. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. The lancet Gastroenterology & hepatology. 2021;6(1):39-56.
Latif A, Sabir S, Iram S, Gul P, Yousafzai A. Hematological And Clinical Analysis of Hepatitis B Patients from Quetta, Pakistan. Pak-Euro Journal of Medical and Life Sciences. 2022;5(2):275-82.
Stasi C, Silvestri C, Voller F. Update on hepatitis C epidemiology: unaware and untreated infected population could be the key to elimination. SN comprehensive clinical medicine. 2020;2(12):2808-15.
Umutesi J, Liu CY, Penkunas MJ, Makuza JD, Ntihabose CK, Umuraza S, Niyikora J, Serumondo J, Gupta N, Nsanzimana S. Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. BMJ open. 2019;9(7):e029743.
Thompson LH. Behaviours, networks, and sequences: HIV epidemics among people who inject drugs in Pakistan. 2020.
Comarmond C, Lorin V, Marques C, Maciejewski-Duval A, Joher N, Planchais C, Touzot M, Biard L, Hieu T, Quiniou V, Desbois AC. TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. Journal of Hepatology. 2019;71(5):908-19.
Yang B, Luo Y, Wei X, Kan J. Polysaccharide from Hovenia dulcis (Guaizao) improves pancreatic injury and regulates liver glycometabolism to alleviate STZ-induced type 1 diabetes mellitus in rats. International Journal of Biological Macromolecules. 2022;214:655-63.
Wróblewska A, Bielawski KP, Sikorska K. Occult infection with hepatitis C virus: looking for clear-cut boundaries and methodological consensus. Journal of Clinical Medicine. 2021;10(24):5874.
Koo V, Tian F, Wong WW. Cost‐effectiveness analysis of hepatitis C virus (HCV) point‐of‐care assay for HCV screening. Liver International. 2022;42(4):787-95.
Luckett K, Kaiser TE, Bari K, Safdar K, Schoech MR, Apewokin S, Diwan TS, Cuffy MC, Anwar N, Shah SA. Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients. Journal of the American College of Surgeons. 2019;228(4):560-7.
Getie B, Ayalew G, Amsalu A, Ferede G, Yismaw G, Tessema B. Seroprevalence and associated factors of hepatitis B and C virus among pulmonary tuberculosis patients attending health facilities in Gondar Town, Northwest Ethiopia. Infection and Drug Resistance. 2021:3599-608.
Naveed A, Khattak MI, Ismail MO, Khattak SN, Rehman S, Saddiqa I. Frequency of chronic Hepatitis B and Hepatitis C seropositivity in haemodialysis patients; A single center study. The Professional Medical Journal. 2022;29(10):1520-5.
Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, Goodkin DA, Pisoni RL. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney international. 2019;95(4):939-47.
Ozaras R, Leblebicioglu H. Global epidemiology of chronic hepatitis C virus infection. Viral Hepatitis: Chronic Hepatitis C. 2019:1-24.
Balasubramanian M. Covid 19-The new age pandemic. Notion Press; 2020.
Akhtar S, Nasir JA, Usman M, Sarwar A, Majeed R, Billah B. The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis. PloS one. 2020;15(5):e0232931.
Ali N, Hussain W, Hayat A, Shah T, Wen R, Zeb I, Malik AA, Ramzan R, Rehman MU, Khan I. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study. European journal of gastroenterology & hepatology. 2019;31(1):29-33.
Khokhar N, Alam AY, Naz F, Mahmud SN. Risk factors for hepatitis C virus infection in patients on long-term hemodialysis. J Coll Physicians Surg Pak. 2005;15(6):326-8.
Subhan F, Khan RA. Viral Hepatitis B and C in hemodialysis patients: A study from Khyber Pakhtunkhwa, Pakistan. National Editorial Advisory Board. 2019;30(9).
Anjum MU, Khan MS, Afridi NM, Shah SH. Hepatitis B and C Virus Infections: In Haemodialysis Patients In Abbottabad, Pakistan. The Professional Medical Journal. 2015;22(10):1284-8.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Pak-Euro Journal of Medical and Life Sciences